Amylyx Pharmaceuticals, Inc.

The current price of AMLX is 2.00 USD — it has decreased by 0.50% in the past 24 hours.

Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Amylyx Pharmaceuticals, Inc. stocks are traded under the ticker AMLX.

Amylyx Pharmaceuticals, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.

One year price forecast for Amylyx Pharmaceuticals, Inc. has a max estimate of 8.00 USD and a min estimate of 3.00 USD.

AMLX earnings for the last quarter are 0.30 USD whereas the estimation was 0.44 USD which accounts for −31.43% surprise. Estimated earnings for the next quarter are 0.23 USD. See more details about Amylyx Pharmaceuticals, Inc. earnings.

Yes, you can track Amylyx Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.

AMLX stock has fallen by 23.08% compared to the previous week, the month change is a 36.10% fall, over the last year Amylyx Pharmaceuticals, Inc. has showed a 93.53% decrease.

Like other stocks, AMLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Amylyx Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.

AMLX reached its all-time high on Jan 30, 2023 with the price of 41.93 USD, and its all-time low was 2.07 USD and was reached on Apr 12, 2024.
See other stocks reaching their highest and lowest prices.

As of Apr 18, 2024, the company has 384.00 employees. See our rating of the largest employees — is Amylyx Pharmaceuticals, Inc. on this list?

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Amylyx Pharmaceuticals, Inc. EBITDA is ‪39.89 M‬ USD, and current EBITDA margin is 10.48%. See more stats in Amylyx Pharmaceuticals, Inc. financial statements.